TGFB1 and cancer: Of note, Smad7, an inhibitor of the TGF-β pathway and target of miR-21-3p, was inversely correlated with p53 mutations in the colorectal cancer patient cohort, providing a potential mechanistic explanation for the activation of cancer-associated fibroblasts.